Media Center

Areva Pharmaceuticals is excited to announce three new products to our ever-expanding portfolio:

Georgetown, IN, July 27, 2015 Capecitabine Tablets, USP 500mg comes in a 120 tablet bottle and is used as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine tablets are non-inferior to5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent capecitabine tablets in the adjuvant treatment of Dukes’ C colon cancer.

Erlotinib is sold by Areva in 25mg, 100mg, and 150mg strengths, all in 30 tablet bottles. Erlotinib is used in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.

Imatinib Mesylate is sold by Areva in 100mg (90 tablets) and 400mg (30 tablets) bottles. Imatinib is used in treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

Categories: News